REVIEW: Induction of Systemic Antitumour Resistance with Targeted Polymers
Conjugates based on N-(2-hydroxypropyl)methacrylamide (HPMA) represent a new generation of antibody-targeted polymeric anticancer drugs with both cytotoxic and immunoprotecting-immunomobilizing activity. 20-90% of mice that are cured of EL4 mouse T-cell lymphoma, BCL1 mouse B-cell leukaemia and 38C1...
Gespeichert in:
| Veröffentlicht in: | Scandinavian Journal of Immunology 2005-07, Vol.62 (s1), p.100-105 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 105 |
|---|---|
| container_issue | s1 |
| container_start_page | 100 |
| container_title | Scandinavian Journal of Immunology |
| container_volume | 62 |
| creator | Rihova, B Strohalm, J Kovar, M Mrkvan, T Subr, V Hovorka, O Sirova, M Rozprimova, L Kubackova, K Ulbrich, K |
| description | Conjugates based on N-(2-hydroxypropyl)methacrylamide (HPMA) represent a new generation of antibody-targeted polymeric anticancer drugs with both cytotoxic and immunoprotecting-immunomobilizing activity. 20-90% of mice that are cured of EL4 mouse T-cell lymphoma, BCL1 mouse B-cell leukaemia and 38C13 mouse B-cell lymphoma by injection of doxorubicin-HPMA conjugate develop a long-lasting memory and systemic antitumour resistance. It is suggested that the main activity of the polymeric drug, directly after application is - due to the high level of the drug - of cytotoxic and cytostatic nature. Thereafter, long-term conjugates persist at low concentration in the circulation, which are capable of mobilizing the defence mechanisms of the host. Until now, seven patients with generalized carcinoma were treated with doxorubicin-HPMA-human-Ig conjugate. Disease stabilization, lasting from 6 to more than 18 months, was recorded. |
| doi_str_mv | 10.1111/j.1365-3083.2005.01617.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_20314202</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20314202</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_203142023</originalsourceid><addsrcrecordid>eNqNisFOAjEQQBuDiYv6D3PytnXasYvxRswa4USQ6JFslgFKdlvZaaP8vcb4AbzLO7ynFBjU5pf7gzZUuZLwkbRFdBpNZSb6-0IVf8G6ajJSBRKasiJLV2osckA0hM4Var6s32f1xxPMwia3yccAcQtvJ0nc-xamIfmU-5gHWLJ4SU1oGb582sOqGXaceAOL2J16HuRGXW6bTvj239fq7qVePb-Wn0M8Zpa07r203HVN4JhlbZHMg0VLZ48_PWxHqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20314202</pqid></control><display><type>article</type><title>REVIEW: Induction of Systemic Antitumour Resistance with Targeted Polymers</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Rihova, B ; Strohalm, J ; Kovar, M ; Mrkvan, T ; Subr, V ; Hovorka, O ; Sirova, M ; Rozprimova, L ; Kubackova, K ; Ulbrich, K</creator><creatorcontrib>Rihova, B ; Strohalm, J ; Kovar, M ; Mrkvan, T ; Subr, V ; Hovorka, O ; Sirova, M ; Rozprimova, L ; Kubackova, K ; Ulbrich, K</creatorcontrib><description>Conjugates based on N-(2-hydroxypropyl)methacrylamide (HPMA) represent a new generation of antibody-targeted polymeric anticancer drugs with both cytotoxic and immunoprotecting-immunomobilizing activity. 20-90% of mice that are cured of EL4 mouse T-cell lymphoma, BCL1 mouse B-cell leukaemia and 38C13 mouse B-cell lymphoma by injection of doxorubicin-HPMA conjugate develop a long-lasting memory and systemic antitumour resistance. It is suggested that the main activity of the polymeric drug, directly after application is - due to the high level of the drug - of cytotoxic and cytostatic nature. Thereafter, long-term conjugates persist at low concentration in the circulation, which are capable of mobilizing the defence mechanisms of the host. Until now, seven patients with generalized carcinoma were treated with doxorubicin-HPMA-human-Ig conjugate. Disease stabilization, lasting from 6 to more than 18 months, was recorded.</description><identifier>ISSN: 0301-6323</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.1111/j.1365-3083.2005.01617.x</identifier><language>eng</language><ispartof>Scandinavian Journal of Immunology, 2005-07, Vol.62 (s1), p.100-105</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Rihova, B</creatorcontrib><creatorcontrib>Strohalm, J</creatorcontrib><creatorcontrib>Kovar, M</creatorcontrib><creatorcontrib>Mrkvan, T</creatorcontrib><creatorcontrib>Subr, V</creatorcontrib><creatorcontrib>Hovorka, O</creatorcontrib><creatorcontrib>Sirova, M</creatorcontrib><creatorcontrib>Rozprimova, L</creatorcontrib><creatorcontrib>Kubackova, K</creatorcontrib><creatorcontrib>Ulbrich, K</creatorcontrib><title>REVIEW: Induction of Systemic Antitumour Resistance with Targeted Polymers</title><title>Scandinavian Journal of Immunology</title><description>Conjugates based on N-(2-hydroxypropyl)methacrylamide (HPMA) represent a new generation of antibody-targeted polymeric anticancer drugs with both cytotoxic and immunoprotecting-immunomobilizing activity. 20-90% of mice that are cured of EL4 mouse T-cell lymphoma, BCL1 mouse B-cell leukaemia and 38C13 mouse B-cell lymphoma by injection of doxorubicin-HPMA conjugate develop a long-lasting memory and systemic antitumour resistance. It is suggested that the main activity of the polymeric drug, directly after application is - due to the high level of the drug - of cytotoxic and cytostatic nature. Thereafter, long-term conjugates persist at low concentration in the circulation, which are capable of mobilizing the defence mechanisms of the host. Until now, seven patients with generalized carcinoma were treated with doxorubicin-HPMA-human-Ig conjugate. Disease stabilization, lasting from 6 to more than 18 months, was recorded.</description><issn>0301-6323</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqNisFOAjEQQBuDiYv6D3PytnXasYvxRswa4USQ6JFslgFKdlvZaaP8vcb4AbzLO7ynFBjU5pf7gzZUuZLwkbRFdBpNZSb6-0IVf8G6ajJSBRKasiJLV2osckA0hM4Var6s32f1xxPMwia3yccAcQtvJ0nc-xamIfmU-5gHWLJ4SU1oGb582sOqGXaceAOL2J16HuRGXW6bTvj239fq7qVePb-Wn0M8Zpa07r203HVN4JhlbZHMg0VLZ48_PWxHqw</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>Rihova, B</creator><creator>Strohalm, J</creator><creator>Kovar, M</creator><creator>Mrkvan, T</creator><creator>Subr, V</creator><creator>Hovorka, O</creator><creator>Sirova, M</creator><creator>Rozprimova, L</creator><creator>Kubackova, K</creator><creator>Ulbrich, K</creator><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20050701</creationdate><title>REVIEW: Induction of Systemic Antitumour Resistance with Targeted Polymers</title><author>Rihova, B ; Strohalm, J ; Kovar, M ; Mrkvan, T ; Subr, V ; Hovorka, O ; Sirova, M ; Rozprimova, L ; Kubackova, K ; Ulbrich, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_203142023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rihova, B</creatorcontrib><creatorcontrib>Strohalm, J</creatorcontrib><creatorcontrib>Kovar, M</creatorcontrib><creatorcontrib>Mrkvan, T</creatorcontrib><creatorcontrib>Subr, V</creatorcontrib><creatorcontrib>Hovorka, O</creatorcontrib><creatorcontrib>Sirova, M</creatorcontrib><creatorcontrib>Rozprimova, L</creatorcontrib><creatorcontrib>Kubackova, K</creatorcontrib><creatorcontrib>Ulbrich, K</creatorcontrib><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Scandinavian Journal of Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rihova, B</au><au>Strohalm, J</au><au>Kovar, M</au><au>Mrkvan, T</au><au>Subr, V</au><au>Hovorka, O</au><au>Sirova, M</au><au>Rozprimova, L</au><au>Kubackova, K</au><au>Ulbrich, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>REVIEW: Induction of Systemic Antitumour Resistance with Targeted Polymers</atitle><jtitle>Scandinavian Journal of Immunology</jtitle><date>2005-07-01</date><risdate>2005</risdate><volume>62</volume><issue>s1</issue><spage>100</spage><epage>105</epage><pages>100-105</pages><issn>0301-6323</issn><eissn>1365-2567</eissn><abstract>Conjugates based on N-(2-hydroxypropyl)methacrylamide (HPMA) represent a new generation of antibody-targeted polymeric anticancer drugs with both cytotoxic and immunoprotecting-immunomobilizing activity. 20-90% of mice that are cured of EL4 mouse T-cell lymphoma, BCL1 mouse B-cell leukaemia and 38C13 mouse B-cell lymphoma by injection of doxorubicin-HPMA conjugate develop a long-lasting memory and systemic antitumour resistance. It is suggested that the main activity of the polymeric drug, directly after application is - due to the high level of the drug - of cytotoxic and cytostatic nature. Thereafter, long-term conjugates persist at low concentration in the circulation, which are capable of mobilizing the defence mechanisms of the host. Until now, seven patients with generalized carcinoma were treated with doxorubicin-HPMA-human-Ig conjugate. Disease stabilization, lasting from 6 to more than 18 months, was recorded.</abstract><doi>10.1111/j.1365-3083.2005.01617.x</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-6323 |
| ispartof | Scandinavian Journal of Immunology, 2005-07, Vol.62 (s1), p.100-105 |
| issn | 0301-6323 1365-2567 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20314202 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; IngentaConnect Free/Open Access Journals; Wiley Online Library All Journals; PubMed Central |
| title | REVIEW: Induction of Systemic Antitumour Resistance with Targeted Polymers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A59%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=REVIEW:%20Induction%20of%20Systemic%20Antitumour%20Resistance%20with%20Targeted%20Polymers&rft.jtitle=Scandinavian%20Journal%20of%20Immunology&rft.au=Rihova,%20B&rft.date=2005-07-01&rft.volume=62&rft.issue=s1&rft.spage=100&rft.epage=105&rft.pages=100-105&rft.issn=0301-6323&rft.eissn=1365-2567&rft_id=info:doi/10.1111/j.1365-3083.2005.01617.x&rft_dat=%3Cproquest%3E20314202%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20314202&rft_id=info:pmid/&rfr_iscdi=true |